Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC

HKG Epitherapeutics

Status: Withdrawn

Conditions: Prostate Adenocarcinoma; Prostate Cancer Metastatic; Prostate Cancer

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT03494803

HKG-KZ-PRAD-103

Details and patient eligibility

About

Prostate cancer is a leading cause of mortality and morbidity.

The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC, T-cells and circulated tumor DNA in prostate cancer patients.

Sex: Male

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent: The patient must sign the appropriate approved informed consent documents in the presence of the designated staff

Exclusion criteria

• Pregnant women
• Minors (subjects less than 18 years of age)
• Prisoners
• Patients having other than one cancer
• Subjects unable to consent for themselves
• Symptomatic of acute prostatitis

Trial design

0 participants in 2 patient groups

Control

Prostate Cancer